200,000+ products from a single source!
sales@angenechem.com
Home > Other Building Blocks > 182133-25-1
182133-25-1 | Benzo[b]thiophene-6-ol, 2-(4-methoxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-
CAS No: 182133-25-1 Catalog No: AG0023F4 MDL No:
Product Description
Catalog Number:
AG0023F4
Chemical Name:
Benzo[b]thiophene-6-ol, 2-(4-methoxyphenyl)-3-[4-[2-(1-piperidinyl)ethoxy]phenoxy]-
CAS Number:
182133-25-1
Molecular Formula:
C28H29NO4S
Molecular Weight:
475.5992
IUPAC Name:
2-(4-methoxyphenyl)-3-[4-(2-piperidin-1-ylethoxy)phenoxy]-1-benzothiophen-6-ol
InChI:
InChI=1S/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3
InChI Key:
MCGDSOGUHLTADD-UHFFFAOYSA-N
SMILES:
COc1ccc(cc1)c1sc2c(c1Oc1ccc(cc1)OCCN1CCCCC1)ccc(c2)O
UNII:
E569WG6E60
Properties
Complexity:
601
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
475.182g/mol
Formal Charge:
0
Heavy Atom Count:
34
Hydrogen Bond Acceptor Count:
6
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
475.603g/mol
Monoisotopic Mass:
475.182g/mol
Rotatable Bond Count:
8
Topological Polar Surface Area:
79.4A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
6.6
Literature
| Title | Journal |
|---|---|
| Preventive therapy for breast cancer. | Current oncology reports 20121201 |
| Breast cancer incidence in postmenopausal women with osteoporosis or low bone mass using arzoxifene. | Breast cancer research and treatment 20120701 |
| Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20120301 |
| An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis. | Maturitas 20120301 |
| Gynecologic effects of arzoxifene in postmenopausal women with osteoporosis or low bone mass. | Menopause (New York, N.Y.) 20120101 |
| Post-traumatic stress disorder: the neurobiological impact of psychological trauma. | Dialogues in clinical neuroscience 20110901 |
| Preventive therapy for breast cancer: a consensus statement. | The Lancet. Oncology 20110501 |
| Impact of metal-induced degradation on the determination of pharmaceutical compound purity and a strategy for mitigation. | Journal of pharmaceutical and biomedical analysis 20110405 |
| Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20110201 |
| Prevention of breast cancer by newer SERMs in the future. | Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 20110101 |
| A Preclinical Evaluation of Antrodia camphorata Alcohol Extracts in the Treatment of Non-Small Cell Lung Cancer Using Non-Invasive Molecular Imaging. | Evidence-based complementary and alternative medicine : eCAM 20110101 |
| Raloxifene and desmethylarzoxifene block estrogen-induced malignant transformation of human breast epithelial cells. | PloS one 20110101 |
| A role for estrogen receptor phosphorylation in the resistance to tamoxifen. | International journal of breast cancer 20110101 |
| Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20101001 |
| New selective estrogen receptor modulators (SERMs) in development. | Current osteoporosis reports 20100901 |
| Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass. | Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 20100701 |
| Developing drugs to treat osteoporosis: lessons learned? | Expert opinion on pharmacotherapy 20100401 |
| Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. | Menopause (New York, N.Y.) 20100101 |
| Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? | Obstetrics and gynecology international 20100101 |
| Selective estrogen receptor modulator (SERM) for the treatment of osteoporosis in postmenopausal women: focus on lasofoxifene. | Clinical interventions in aging 20100101 |
| Alternative strategies for the treatment of classical congenital adrenal hyperplasia: pitfalls and promises. | International journal of pediatric endocrinology 20100101 |
| Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations. | Breast cancer research : BCR 20100101 |
| Modulators of androgen and estrogen receptor activity. | Critical reviews in eukaryotic gene expression 20100101 |
| Selective estrogen receptor modulator delivery of quinone warheads to DNA triggering apoptosis in breast cancer cells. | ACS chemical biology 20091218 |
| Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. | Journal of women's health (2002) 20091001 |
| Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1. | Molecular endocrinology (Baltimore, Md.) 20090901 |
| Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass. | The Journal of clinical endocrinology and metabolism 20090701 |
| New selective estrogen and androgen receptor modulators. | Current opinion in rheumatology 20090701 |
| Comparative methods for analysis of protein covalent modification by electrophilic quinoids formed from xenobiotics. | Bioconjugate chemistry 20090401 |
| Emerging drugs for postmenopausal osteoporosis. | Expert opinion on emerging drugs 20090301 |
| Structural modulation of oxidative metabolism in design of improved benzothiophene selective estrogen receptor modulators. | Drug metabolism and disposition: the biological fate of chemicals 20090101 |
| Designing the ideal selective estrogen receptor modulator--an achievable goal? | Menopause (New York, N.Y.) 20090101 |
| The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors. | BMC cancer 20090101 |
| Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis. | Therapeutics and clinical risk management 20090101 |
| Lasofoxifene: Evidence of its therapeutic value in osteoporosis. | Core evidence 20090101 |
| Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. | International journal of women's health 20090101 |
| Treating postmenopausal osteoporosis in women at increased risk of fracture - critical appraisal of bazedoxifene: a review. | International journal of women's health 20090101 |
| Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro. | Breast cancer : basic and clinical research 20090101 |
| The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice. | British journal of cancer 20080422 |
| Selective estrogen receptor modulators: an update on recent clinical findings. | Obstetrical & gynecological survey 20080301 |
| [Status of novel bone-targeting SERMs in development]. | Nihon rinsho. Japanese journal of clinical medicine 20071128 |
| Uterine peroxidase-catalyzed formation of diquinone methides from the selective estrogen receptor modulators raloxifene and desmethylated arzoxifene. | Chemical research in toxicology 20071101 |
| Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20071101 |
| Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene. | ChemMedChem 20071001 |
| Structural modulation of reactivity/activity in design of improved benzothiophene selective estrogen receptor modulators: induction of chemopreventive mechanisms. | Molecular cancer therapeutics 20070901 |
| Effect of estrogens on skin aging and the potential role of SERMs. | Clinical interventions in aging 20070901 |
| Update on bazedoxifene: a novel selective estrogen receptor modulator. | Clinical interventions in aging 20070901 |
| Benzothiophene selective estrogen receptor modulators with modulated oxidative activity and receptor affinity. | Journal of medicinal chemistry 20070531 |
| The future of the new selective estrogen receptor modulators. | Menopause international 20070301 |
| Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. | Drugs & aging 20070101 |
| Interactions of the human cytosolic sulfotransferases and steroid sulfatase in the metabolism of tibolone and raloxifene. | The Journal of steroid biochemistry and molecular biology 20070101 |
| Arzoxifene: the evidence for its development in the management of breast cancer. | Core evidence 20070101 |
| The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20061001 |
| Developments in the pharmacotherapeutic management of osteoporosis. | Expert opinion on pharmacotherapy 20060801 |
| Chemical modification modulates estrogenic activity, oxidative reactivity, and metabolic stability in 4'F-DMA, a new benzothiophene selective estrogen receptor modulator. | Chemical research in toxicology 20060601 |
| Arzoxifene: the development and clinical outcome of an ideal SERM. | Expert opinion on investigational drugs 20060301 |
| Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal women. | Drugs 20060101 |
| Estrogen receptors as therapeutic targets in breast cancer. | Current topics in medicinal chemistry 20060101 |
| Prevention of breast cancer using selective oestrogen receptor modulators (SERMs). | Breast cancer research : BCR 20060101 |
| Effect of the selective estrogen receptor modulator arzoxifene on repopulation of hormone-responsive breast cancer xenografts between courses of chemotherapy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20051115 |
| Breast cancer chemoprevention: a review of selective estrogen receptor modulators. | Clinical journal of oncology nursing 20050601 |
| Efficient access to 2-aryl-3-substituted benzo[b]thiophenes. | The Journal of organic chemistry 20050429 |
| Endocrine treatment options for advanced breast cancer--the role of fulvestrant. | European journal of cancer (Oxford, England : 1990) 20050201 |
| Bioactivation of the selective estrogen receptor modulator desmethylated arzoxifene to quinoids: 4'-fluoro substitution prevents quinoid formation. | Chemical research in toxicology 20050201 |
| Endocrinology and hormone therapy in breast cancer: selective oestrogen receptor modulators and downregulators for breast cancer - have they lost their way? | Breast cancer research : BCR 20050101 |
| Rexinoids may be ready for prime time in prevention, but challenges remain. | Journal of the National Cancer Institute 20041215 |
| Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. | Cancer treatment reviews 20041201 |
| Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. | Current opinion in investigational drugs (London, England : 2000) 20041001 |
| Arzoxifene: a promising new selective estrogen receptor modulator for clinical chemoprevention of breast cancer. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040815 |
| Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. | Clinical cancer research : an official journal of the American Association for Cancer Research 20040815 |
| A new MCF-7 breast cancer cell line resistant to the arzoxifene metabolite desmethylarzoxifene. | Molecular and cellular endocrinology 20040531 |
| The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer. | Cancer research 20040515 |
| The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells. | Molecular and cellular endocrinology 20040430 |
| The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. | Best practice & research. Clinical endocrinology & metabolism 20040301 |
| Models of breast cancer: is merging human and animal models the future? | Breast cancer research : BCR 20040101 |
| Effects of long-term administration of N-3 polyunsaturated fatty acids (PUFA) and selective estrogen receptor modulator (SERM) derivatives in ovariectomized (OVX) mice. | Journal of cellular biochemistry 20031001 |
| Selective estrogen receptor modulators as inhibitors of repopulation of human breast cancer cell lines after chemotherapy. | Clinical cancer research : an official journal of the American Association for Cancer Research 20031001 |
| Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model. | Cancer research 20031001 |
| Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. | Annals of oncology : official journal of the European Society for Medical Oncology 20030901 |
| Arzoxifene Eli Lilly. | IDrugs : the investigational drugs journal 20030901 |
| Arzoxifene as therapy for endometrial cancer. | Gynecologic oncology 20030801 |
| A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. | Gynecologic oncology 20030701 |
| Novel therapies for osteoporosis. | Expert opinion on investigational drugs 20030401 |
| Phase II, randomized, double-blind study of two dose levels of arzoxifene in patients with locally advanced or metastatic breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030315 |
| Current status of selective estrogen receptor modulators (SERMs). | Cancer journal (Sudbury, Mass.) 20030101 |
| Pharmacokinetics of selective estrogen receptor modulators. | Clinical pharmacokinetics 20030101 |
| Advances in breast cancer treatment and prevention: preclinical studies on aromatase inhibitors and new selective estrogen receptor modulators (SERMs). | Breast cancer research : BCR 20030101 |
| Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. | Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 20021201 |
| Arzoxifene in breast cancer. | European journal of cancer (Oxford, England : 1990) 20021101 |
| Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268. | Clinical cancer research : an official journal of the American Association for Cancer Research 20021001 |
| SERMs: current status and future trends. | Critical reviews in oncology/hematology 20020701 |
| Novel therapeutic options for osteoporosis. | Current opinion in rheumatology 20020701 |
| A review of selective estrogen receptor modulators in the treatment of breast and endometrial cancer. | Seminars in oncology 20020601 |
| Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques. | Psychoneuroendocrinology 20020501 |
| Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. | Current opinion in obstetrics & gynecology 20020201 |
| Selective estrogen receptor modulators as a new therapeutic drug group: concept to reality in a decade. | Clinical breast cancer 20020101 |
| Selective estrogen receptor modulators: tissue actions and potential for CNS protection. | CNS drug reviews 20020101 |
| Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. | Cancer research 20011201 |
| Effects of the new selective estrogen receptor modulator LY353381.HCl (Arzoxifene) on human endometrial cancer growth in athymic mice. | Clinical cancer research : an official journal of the American Association for Cancer Research 20011201 |
| Beyond tamoxifen new endpoints for breast cancer chemoprevention, new drugs for breast cancer prevention. | Annals of the New York Academy of Sciences 20011201 |
| Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms? | The Journal of steroid biochemistry and molecular biology 20011201 |
| Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies. | Clinical cancer research : an official journal of the American Association for Cancer Research 20011201 |
| Analysis of cross-resistance of the selective estrogen receptor modulators arzoxifene (LY353381) and LY117018 in tamoxifen-stimulated breast cancer xenografts. | Clinical cancer research : an official journal of the American Association for Cancer Research 20010801 |
| Phase I study of a third-generation selective estrogen receptor modulator, LY353381.HCL, in metastatic breast cancer. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010401 |
| Selective estrogen receptor modulators for the chemoprevention of prostate cancer. | Urology 20010401 |
| Breast cancer chemoprevention: beyond tamoxifen. | Breast cancer research : BCR 20010101 |
| Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen receptor-alpha. | Endocrinology 20000901 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.